President Donald Trump has signed an executive order to speed up the review of certain psychedelic drugs, specifically those that have been designated as "breakthrough therapies". The move is seen as potentially beneficial for veterans and those struggling with mental health issues. However, critics have raised concerns about safety and oversight.